Impact of a Phone-based Cognitive and Behavioral Therapy on Food Addiction in Patients With Severe or Morbid Obesity
Launched by UNIVERSITY HOSPITAL, TOURS · Nov 10, 2020
Trial Information
Current as of August 19, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effects of a phone-based therapy called cognitive behavioral therapy (CBT) on people with severe obesity and food addiction. Food addiction means having a strong craving for certain unhealthy foods, which can lead to eating problems and negatively affect a person's health and quality of life. The researchers want to see if this therapy can help reduce food addiction, improve weight management, and enhance overall well-being for participants over 18 weeks, compared to those receiving regular care.
To join the study, participants need to be between 18 and 65 years old, have a body mass index (BMI) of 35 or higher (which indicates severe obesity), and be diagnosed with food addiction. They also need to be able to participate in phone sessions and give their consent to take part. Throughout the trial, participants will attend 12 therapy sessions over the 18 weeks, where they will learn techniques to manage their cravings and improve their eating habits. This trial aims to provide valuable information on how effective phone-based therapy can be for individuals dealing with these challenges.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 18-65 years
- • BMI ≥35kg/m² (morbid or severe obesity)
- • First appointment to a physician specialized in nutrition
- • "Food addiction diagnosis" according to the YFAS 2.0
- • Affiliated to the French national health service
- • Consent signed
- Exclusion Criteria:
- • Difficulties in understanding the self-administered questionnaires, including illiteracy
- • Impossibility to participate to the CBT sessions (i.e., no phone, scheduled unavailability)
- • Not eligible for CBT (i.e., cognitive disorders, hearing disorders)
- • Antecedent of monogenic or oligogenic obesity (MC4R mutation)
- • Severe alcohol use disorder (at least 6 out of 11 DSM-5 criteria for alcohol use disorder)
- • Current medication with a significant adverse effect on eating behavior (i.e., lithium, neuroleptic/antipsychotic)
- • Discrepancy between self-administered questionnaires and the clinical interview conducted prior to inclusion (for the assessment of food addiction diagnosis).
- • Condition associated with important weight variations (i.e., oedema related to severe cardiac insufficiency, renal insufficiency, hepatic insufficiency with cirrhosis, exudative enteropathy)
- • Participation to another psychological or pharmacological interventional study that could impact our primary or secondary outcomes
- • Wearing a pace-maker or metal prosthesis
- • Person under tutorship or curatorship
About University Hospital, Tours
The University Hospital of Tours, a leading academic medical institution in France, is dedicated to advancing healthcare through innovative clinical research and patient-centered care. With a strong emphasis on collaboration between researchers, clinicians, and community partners, the hospital fosters a dynamic environment for conducting high-quality clinical trials across various medical disciplines. Its commitment to excellence in patient safety, ethical standards, and scientific integrity positions the University Hospital of Tours as a pivotal contributor to the development of new therapies and health solutions, ultimately enhancing patient outcomes and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Angers, , France
Brest, , France
Caen, , France
Cherbourg, , France
Nantes, , France
Poitiers, , France
Reims, , France
Rennes, , France
Tours, , France
Patients applied
Trial Officials
Paul BRUNAULT, MD
Study Director
University Hospital, Tours
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials